Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.00 Insider Own0.70% Shs Outstand115.58M Perf Week-11.75%
Market Cap625.29M Forward P/E- EPS next Y-0.99 Insider Trans17.59% Shs Float103.87M Perf Month-7.04%
Income-109.80M PEG- EPS next Q-0.25 Inst Own68.60% Short Float19.46% Perf Quarter-44.91%
Sales101.70M P/S6.15 EPS this Y39.40% Inst Trans-0.55% Short Ratio14.37 Perf Half Y-46.33%
Book/sh-1.26 P/B- EPS next Y15.40% ROA-89.00% Target Price14.00 Perf Year-41.51%
Cash/sh0.54 P/C10.02 EPS next 5Y5.60% ROE85.20% 52W Range5.10 - 13.84 Perf YTD-31.52%
Dividend- P/FCF- EPS past 5Y-7.00% ROI-367.80% 52W High-60.91% Beta1.48
Dividend %- Quick Ratio0.70 Sales past 5Y117.70% Gross Margin- 52W Low6.08% ATR0.54
Employees306 Current Ratio0.70 Sales Q/Q-41.40% Oper. Margin-90.50% RSI (14)34.54 Volatility10.40% 9.21%
OptionableYes Debt/Eq- EPS Q/Q-40.70% Profit Margin- Rel Volume0.95 Prev Close5.44
ShortableYes LT Debt/Eq- EarningsFeb 25 BMO Payout- Avg Volume1.41M Price5.41
Recom1.70 SMA20-12.28% SMA50-25.84% SMA200-44.43% Volume1,341,981 Change-0.55%
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Feb-04-16 02:14PM  Merrimack CEO: Face of pharma isn't a bad actor
Jan-20-16 04:36PM  Merrimack Reports Positive Onivyde Data in Pancreatic Cancer +10.39%
Jan-19-16 06:58PM  Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer PR Newswire
Jan-13-16 06:24AM  3 Biotech Stocks Under $10 to Trade for Big Breakouts at TheStreet -8.14%
Jan-11-16 08:00AM  Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE (irinotecan liposome injection) at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium PR Newswire -11.55%
Jan-05-16 08:00AM  Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-15 08:30AM  A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals, Spectranetics and Jinpan International Accesswire
Dec-23-15 04:51PM  Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds
Dec-22-15 04:39PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi
04:16PM  Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration PR Newswire
04:15PM  Merrimack Announces Private Placement of $175 Million of Senior Secured Notes PR Newswire
Dec-15-15 11:20AM  Massachusetts biotechs behind one-in-six drugs approved by FDA this year at bizjournals.com
Dec-14-15 02:14PM  Merrimack Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -5.61%
Dec-13-15 12:34PM  Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)? at Insider Monkey
Dec-12-15 08:40PM  Do Hedge Funds Love Ollies Bargain Outlet Holdings Inc (OLLI)? at Insider Monkey
Dec-08-15 01:17PM  MERRIMACK PHARMACEUTICALS INC Financials
Dec-04-15 08:00AM  Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium PR Newswire +5.31%
Nov-30-15 10:59AM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : November 30, 2015
08:09AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015
Nov-25-15 02:24PM  Baxaltas ONIVYDE NAPOLI-1 Study Sends It to Top of Large-Caps
08:14AM  Hedge Funds Are Buying A. Schulman Inc (SHLM) at Insider Monkey
Nov-24-15 05:02PM  Merrimack CFO Brings Banking, Clinical Chops to Role at The Wall Street Journal
Nov-23-15 08:00AM  Merrimack and Baxalta Announce Publication of the ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study in The Lancet PR Newswire +6.06%
Nov-21-15 01:15PM  JPMorgan Likes These 5 Biotech Stocks at TheStreet
Nov-19-15 02:30PM  Gilead Leads a Biotech Rally at TheStreet
Nov-16-15 03:35PM  Momenta's Cancer Study Enrolment Put on Temporary Hold -5.92%
Nov-10-15 03:03PM  Why Merrimack Pharmaceuticals Inc Is Selling Off Today at Motley Fool -9.06%
02:15PM  Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss
Nov-09-15 10:03PM  Edited Transcript of MACK earnings conference call or presentation 9-Nov-15 9:30pm GMT
05:25PM  Merrimack reports 3Q loss
04:21PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:02PM  Merrimack Reports Third Quarter 2015 Financial Results PR Newswire
07:07AM  Q3 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Nov-06-15 03:25PM  Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?
02:55PM  Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?
02:40PM  Will Intercept (ICPT) Beat Estimates in Q3 Earnings?
01:40PM  Will Inovio (INO) Disappoint Investors this Earnings Season?
Nov-05-15 04:25PM  What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
04:20PM  Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
06:42AM  CEO: THIS is biggest threat to pharm research...
Nov-04-15 10:00AM  Merrimack Pharmaceuticals (Nasdaq: MACK) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Nov-03-15 04:05PM  Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire
03:40PM  Can Endo International's (ENDP) Q3 Earnings Surprise?
Nov-02-15 05:17PM  Will Geron (GERN) Post a Wider-than-Expected Loss in Q3? +6.85%
05:04PM  Will Aerie (AERI) Post a Wider-Than-Expected Loss in Q3?
05:00PM  Will AVEO (AVEO) Pull a Surprise this Earnings Season?
04:45PM  What's in Store for Conatus (CNAT) this Earnings Season?
04:42PM  What to Expect from Radius (RDUS) This Earnings Season
04:40PM  Can Celldex (CLDX) Surprise Estimates in Q3 Earnings?
04:15PM  Will Qorvo (QRVO) Q2 Earnings Beat on Holistic Growth?
Oct-30-15 04:05PM  Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call PR Newswire
01:40PM  Will Prothena (PRTA) Miss Estimates This Earnings Season?
01:35PM  Will Arena's (ARNA) Q3 Loss be Narrower-than-Expected?
08:19AM  Why biotech could be on the verge of a rebound
Oct-27-15 08:45AM  Top Analyst Upgrades and Downgrades: BioDelivery, Merrimack, Silver Wheaton, Valeant, Weatherford and More at 24/7 Wall St.
08:00AM  Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer PR Newswire
Oct-23-15 12:15AM  PharmaEngine Announces U.S. FDA Approves Merrimack's ONIVYDE(TM) (irinotecan liposome injection) PR Newswire +11.02%
Oct-22-15 01:26PM  FDA clears Merrimack's pancreatic cancer drug with warning Reuters -12.99%
01:11PM  Merrimack Announces U.S. FDA Approval of ONIVYDE (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer PR Newswire
01:05PM  Merrimack Pharma Wins FDA Approval of Metastatic Pancreatic Cancer Drug
11:40AM  Merrimack Pharma's cancer drug wins FDA approval Reuters
09:05AM  PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer PR Newswire
02:15AM  Trending Now: MACK
Oct-20-15 10:22AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : October 20, 2015
Oct-11-15 07:21AM  Here's Why Merrimack Pharmaceuticals Slumped in September at Motley Fool
Oct-06-15 10:38AM  Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying
Oct-03-15 09:15AM  5 Big FDA Decisions Expected in October at 24/7 Wall St.
Sep-29-15 04:02PM  Five Biotech Stocks That Could Be M&A Targets After the Selloff at Barrons.com -11.38%
02:49PM  Hedge Funds Have This To Say About Tuesdays Healthcare Flops at Insider Monkey
Sep-24-15 04:00PM  Merrimack Debuts New Website PR Newswire
08:38AM  Will the FDA Approve All 3 of These Cancer Drugs in October? at Motley Fool
Sep-22-15 12:59PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : September 22, 2015
10:18AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : September 22, 2015
Sep-18-15 08:44AM  3 Healthcare Stocks That Cost Less Than a Trip to Chipotle at Motley Fool
Sep-11-15 08:35AM  5 Stocks Ready for Breakouts at TheStreet
Sep-08-15 12:45PM  With pending drug approval, Merrimack Pharma set to be area's next commercial biotech at bizjournals.com +5.77%
Aug-25-15 11:40AM  Merrimack Pharmaceuticals, Inc. Q2 Earnings, 2015
Aug-20-15 12:19PM  10 Biotech Stocks With Catalysts Coming Soon -7.94%
Aug-19-15 09:17AM  5 Stocks Insiders Love Right Now at TheStreet
Aug-13-15 09:20AM  JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015 at 24/7 Wall St.
Aug-12-15 08:44AM  Merrimack Pharmaceuticals (MACK) Catches Eye: Stock Up 5.8%
Aug-11-15 01:55PM  Why Merrimack Pharmaceuticals Inc is Soaring Today at Motley Fool +5.77%
10:50AM  Merrimack Pharmaceuticals' Q2 Loss Wider, Revenues Up - Analyst Blog
04:08AM  Edited Transcript of MACK earnings conference call or presentation 10-Aug-15 8:30pm GMT
Aug-10-15 05:07PM  Merrimack reports 2Q loss
04:30PM  Merrimack Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:10PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:01PM  Merrimack Pharmaceuticals Reports Second Quarter 2015 Financial Results PR Newswire
07:07AM  Q2 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Aug-07-15 03:50PM  Merrimack Pharmaceuticals (MACK): Q2 Earnings Preview - Analyst Blog -5.46%
02:03PM  Merrimack Pharmaceuticals' Stock Tanked in July: Is It Now a Buy? at Motley Fool
Aug-06-15 05:08PM  CFO Moves: Shutterstock, Merrimack Pharmaceuticals, Tribune Media at The Wall Street Journal -7.10%
08:14AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
08:00AM  Merrimack Pharmaceuticals Names Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development PR Newswire
Aug-03-15 08:00AM  Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call PR Newswire
Jul-13-15 05:03PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
Jun-29-15 01:55PM  Baxter's MAA for MM-398 Accepted in International Markets - Analyst Blog -5.10%
Jun-25-15 03:18PM  MM-398 Receiving the Priority Review Designation by US FDA for New Drug Application and the Acceptance of Market Authorization Application by EMA in Post-Gemcitabine Metastatic Pancreatic Cancer PR Newswire
01:20PM  3 Stocks Spiking on Unusual Volume at TheStreet
07:00AM  U.S. FDA Grants Priority Review for MM-398 New Drug Application PR Newswire
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has completed Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398. The company's therapeutic oncology candidates also include MM-302 that is in Phase II clinical trial for the treatment of patients with ErbB2 (HER2)-positive, locally advanced or metastatic breast cancer; MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer, as well as ovarian, breast, and non-small cell lung cancers; and MM-111 that is in a Phase II clinical trial for the treatment of patients with advanced gastric, esophageal, and gastroesophageal junction cancers. In addition, its therapeutic oncology candidates consist of MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has collaboration and license agreements with Baxter International Inc., Baxter Healthcare Corporation, Baxter Healthcare SA, Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, and University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stewart Edward J.Head of CommercialJan 05Option Exercise1.814,0007,24025,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialJan 05Sale8.004,00032,00021,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialDec 01Option Exercise1.815,0009,05026,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialDec 01Sale9.335,00046,65021,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialOct 16Option Exercise1.811,0001,81022,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 16Sale10.001,00010,00021,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 02Option Exercise1.811,0001,81022,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 02Sale9.001,0009,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Option Exercise1.814,0007,24025,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Sale8.004,00032,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialSep 01Option Exercise1.816,00010,86027,385Sep 01 04:11 PM
Stewart Edward J.Head of CommercialSep 01Sale9.886,00059,28021,385Sep 01 04:11 PM
PORTER MICHAEL EDirectorAug 21Buy9.765,00048,800699,448Aug 25 09:13 AM
Stewart Edward J.Head of CommercialAug 17Option Exercise1.816,00010,86027,385Aug 19 04:09 PM
Stewart Edward J.Head of CommercialAug 17Sale10.496,00062,94021,385Aug 19 04:09 PM
PORTER MICHAEL EDirectorAug 14Buy10.183,00030,540694,448Aug 17 09:00 AM
PORTER MICHAEL EDirectorAug 13Buy10.6510,000106,500691,448Aug 17 09:00 AM
Dineen John M.DirectorAug 12Buy10.15100,0001,015,000100,000Aug 13 08:34 AM
PORTER MICHAEL EDirectorAug 12Buy10.1620,000203,200681,448Aug 13 08:30 AM
Lee Vivian SDirectorAug 12Buy10.0510,000100,50030,000Aug 14 09:21 AM
Stewart Edward J.Head of CommercialJul 15Option Exercise1.816,00010,86027,385Jul 17 04:10 PM
Sullivan William A.CFO and TreasurerJul 15Option Exercise2.1215,00031,80026,000Jul 17 04:11 PM
Sullivan William A.CFO and TreasurerJul 15Sale11.8515,000177,75011,000Jul 17 04:11 PM
Stewart Edward J.Head of CommercialJul 15Sale11.846,00071,04021,385Jul 17 04:10 PM
Nielsen Ulrik B.DirectorJun 19Option Exercise2.5640,000102,400266,811Jun 19 09:04 PM
Nielsen Ulrik B.DirectorJun 19Sale12.0240,000480,800226,811Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 18Option Exercise1.812,0003,62023,385Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 18Sale12.002,00024,00021,385Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 15Option Exercise1.816,00010,86027,385Jun 15 06:12 PM
Sullivan William A.CFO and TreasurerJun 15Option Exercise2.1215,00031,80026,000Jun 15 06:13 PM
Sullivan William A.CFO and TreasurerJun 15Sale10.6515,000159,75011,000Jun 15 06:13 PM
Stewart Edward J.Head of CommercialJun 15Sale10.676,00064,02021,385Jun 15 06:12 PM
Schoeberl Birgit M.Head of DiscoveryJun 09Option Exercise2.1262,057131,56165,657Jun 11 08:23 AM
Nielsen Ulrik B.DirectorMay 19Option Exercise2.4740,00098,800266,811May 19 05:04 PM
Nielsen Ulrik B.DirectorMay 19Sale13.0440,000521,600226,811May 19 05:04 PM
Sullivan William A.CFO and TreasurerMay 15Option Exercise2.1215,00031,80026,000May 19 05:02 PM
Stewart Edward J.Head of CommercialMay 15Option Exercise1.818,00014,48029,385May 19 05:03 PM
Stewart Edward J.Head of CommercialMay 15Sale12.338,00098,64021,385May 19 05:03 PM
Sullivan William A.CFO and TreasurerMay 15Sale12.3715,000185,55011,000May 19 05:02 PM
PORTER MICHAEL EDirectorMay 13Buy11.798,28497,668661,448May 15 07:53 AM
Nielsen Ulrik B.DirectorApr 20Option Exercise1.7740,00070,900266,811Apr 20 07:40 PM
Nielsen Ulrik B.DirectorApr 20Sale12.8840,000515,200226,811Apr 20 07:40 PM
Sullivan William A.CFO and TreasurerApr 15Option Exercise2.1215,00031,80026,000Apr 15 06:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolApr 15Option Exercise1.818,00014,48029,385Apr 15 06:07 PM
Stewart Edward J.SVP & Pres, Healthcare SolApr 15Sale12.798,000102,32021,385Apr 15 06:07 PM
Sullivan William A.CFO and TreasurerApr 15Sale12.8715,000193,05011,000Apr 15 06:07 PM
Fehr Gordon J.DirectorApr 13Option Exercise1.7120,00034,200235,143Apr 15 06:07 PM
Fehr Gordon J.DirectorApr 13Sale13.0020,000260,000215,143Apr 15 06:07 PM
CROCKER GARY LDirectorApr 02Option Exercise2.1685,000183,3502,943,961Apr 10 09:41 AM
Mulroy Robert J.President and CEOMar 24Option Exercise1.94447,980868,4791,683,328Mar 25 05:26 PM
PORTER MICHAEL EDirectorMar 24Buy11.705,00058,500653,164Mar 26 08:41 AM
Mulroy Robert J.President and CEOMar 24Sale11.71103,9681,217,4651,509,316Mar 25 05:26 PM
Mulroy Robert J.President and CEOMar 23Option Exercise1.7110,40017,7841,349,716Mar 25 05:26 PM
Mulroy Robert J.President and CEOMar 23Sale11.6910,400121,5761,339,316Mar 25 05:26 PM
PORTER MICHAEL EDirectorMar 20Buy11.775,00058,850648,164Mar 24 09:14 AM
Sullivan William A.CFO and TreasurerMar 19Option Exercise2.1215,00031,80026,000Mar 20 04:58 PM
Nielsen Ulrik B.DirectorMar 19Option Exercise1.7140,00068,400266,811Mar 20 04:57 PM
Nielsen Ulrik B.DirectorMar 19Sale11.9740,000478,800226,811Mar 20 04:57 PM
Sullivan William A.CFO and TreasurerMar 19Sale11.9715,000179,55011,000Mar 20 04:58 PM
Schoeberl Birgit M.Head of DiscoveryMar 17Option Exercise1.7621,33737,62024,937Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 17Option Exercise1.812,0003,62023,385Mar 18 06:47 PM
PORTER MICHAEL EDirectorMar 17Buy11.771,19014,006644,354Mar 19 11:06 AM
Schoeberl Birgit M.Head of DiscoveryMar 17Sale12.0021,337256,0443,600Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 17Sale12.002,00024,00021,385Mar 18 06:47 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 16Option Exercise1.816,00010,86027,385Mar 18 06:47 PM
Schoeberl Birgit M.Head of DiscoveryMar 16Option Exercise1.7120,89735,82424,497Mar 18 08:53 PM
Schoeberl Birgit M.Head of DiscoveryMar 16Sale12.0020,897250,7643,600Mar 18 08:53 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 16Sale11.936,00071,58021,385Mar 18 06:47 PM
Mulroy Robert J.President and CEOMar 05Option Exercise1.7122,38538,2781,361,701Mar 09 04:16 PM
Mulroy Robert J.President and CEOMar 05Sale12.5022,385279,8131,339,316Mar 09 04:16 PM
Nielsen Ulrik B.DirectorMar 04Option Exercise1.7120,00034,200246,811Mar 06 04:34 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 04Option Exercise1.816,00010,86027,385Mar 06 04:34 PM
Stewart Edward J.SVP & Pres, Healthcare SolMar 04Sale12.006,00072,00021,385Mar 06 04:34 PM
Nielsen Ulrik B.DirectorMar 04Sale12.0120,000240,200226,811Mar 06 04:34 PM
PORTER MICHAEL EDirectorMar 02Buy10.935,00054,650638,164Mar 04 07:37 AM
Nielsen Ulrik B.DirectorFeb 23Option Exercise1.7120,00034,200246,811Feb 24 04:20 PM
Nielsen Ulrik B.DirectorFeb 23Sale10.9120,000218,200226,811Feb 24 04:20 PM
Mulroy Robert J.President and CEOFeb 20Option Exercise1.71150,000256,5001,489,316Feb 20 04:14 PM
Mulroy Robert J.President and CEOFeb 20Sale10.94150,0001,641,0001,339,316Feb 20 04:14 PM
Stewart Edward J.SVP & Pres, Healthcare SolFeb 17Option Exercise1.816,00010,86027,385Feb 19 04:44 PM
Stewart Edward J.SVP & Pres, Healthcare SolFeb 17Sale10.316,00061,86021,385Feb 19 04:44 PM